Alcon Inc. logo

Alcon Inc.

ALC

NYSEHealthcareMedical - Specialties

Previous close

$73.63

+$0.70 · +0.96%

Aug 21, 4:00 PM ET

ALC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

74

Undervalued

Momentum

39

Weakening

Sentiment

62

Bullish

Risk resilience

68

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Industry
Medical - Specialties
Sector
Healthcare
Headquarters
CH
CEO
David J. Endicott
Listed since
Apr 9, 2019
Employees
25,000

Market position

Day range

Current $73.63

52-week range

Current $73.63

Open
$72.80
Previous close
$72.93
Volume
994.18K
0.47× average
Average volume
2.13M
Average daily volume
Market cap
35.91B USD
Beta
0.69
Market reference 1
50-day average
$69.1474
+6.48% above average
200-day average
$74.6501
-1.37% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
42.73B USD
EV / EBITDA
18.17×
Earnings yield
2.51%
Free cash flow yield
4.12%

Profitability & efficiency

Return on equity
4.45%
Return on assets
3.11%
Return on invested capital
3.94%

Financial health

Current ratio
2.12×
Altman Z-score
2.85
Piotroski F-score
8 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends61%40%20%-1%Gross margin, FY2021: 56.11%Gross margin, FY2022: 54.47%Gross margin, FY2023: 55.49%Gross margin, FY2024: 55.61%Gross margin, FY2025: 55.24%Operating margin, FY2021: 7.00%Operating margin, FY2022: 7.71%Operating margin, FY2023: 10.99%Operating margin, FY2024: 14.26%Operating margin, FY2025: 13.08%Net margin, FY2021: 4.54%Net margin, FY2022: 3.84%Net margin, FY2023: 10.30%Net margin, FY2024: 10.27%Net margin, FY2025: 9.42%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 56.11%. Gross margin FY2022 54.47%. Gross margin FY2023 55.49%. Gross margin FY2024 55.61%. Gross margin FY2025 55.24%. Operating margin FY2021 7.00%. Operating margin FY2022 7.71%. Operating margin FY2023 10.99%. Operating margin FY2024 14.26%. Operating margin FY2025 13.08%. Net margin FY2021 4.54%. Net margin FY2022 3.84%. Net margin FY2023 10.30%. Net margin FY2024 10.27%. Net margin FY2025 9.42%.

Income trends

Revenue

10.4B USD+4.94%

Operating income

1.36B USD-3.75%

Net income

980M USD-3.73%
Income trends across reported periods11.41B USD7.38B USD3.35B USD−671.6M USDRevenue, FY2021: 8.29B USDRevenue, FY2022: 8.72B USDRevenue, FY2023: 9.46B USDRevenue, FY2024: 9.91B USDRevenue, FY2025: 10.4B USDOperating income, FY2021: 580M USDOperating income, FY2022: 672M USDOperating income, FY2023: 1.04B USDOperating income, FY2024: 1.41B USDOperating income, FY2025: 1.36B USDNet income, FY2021: 376M USDNet income, FY2022: 335M USDNet income, FY2023: 974M USDNet income, FY2024: 1.02B USDNet income, FY2025: 980M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 8.29B USD. Revenue FY2022 8.72B USD. Revenue FY2023 9.46B USD. Revenue FY2024 9.91B USD. Revenue FY2025 10.4B USD. Operating income FY2021 580M USD. Operating income FY2022 672M USD. Operating income FY2023 1.04B USD. Operating income FY2024 1.41B USD. Operating income FY2025 1.36B USD. Net income FY2021 376M USD. Net income FY2022 335M USD. Net income FY2023 974M USD. Net income FY2024 1.02B USD. Net income FY2025 980M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue10.4B USD9.91B USD9.46B USD8.72B USD8.29B USD
Cost of goods sold4.66B USD4.4B USD4.21B USD3.97B USD3.64B USD
Gross profit5.75B USD5.51B USD5.25B USD4.75B USD4.65B USD
Research and development990M USD876M USD859M USD702M USD842M USD
Selling, general, and administrative3.45B USD3.25B USD3.21B USD3.07B USD3.08B USD
Operating expenses4.39B USD4.1B USD4.21B USD4.08B USD4.07B USD
Interest income74M USD81.45M USD34M USD16.52M USD3.01M USD
Interest expense204M USD186.18M USD189M USD138.4M USD120.26M USD
Depreciation and amortization1.19B USD1.23B USD1.22B USD1.16B USD1.22B USD
Operating income1.36B USD1.41B USD1.04B USD672M USD580M USD
Net income980M USD1.02B USD974M USD335M USD376M USD

Company facts updated Aug 24, 2026.

ALC peers

ETFs holding ALC

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research ALC

research.disclaimer